Although biopsy-verified celiac disease and intestinal inflammation were associated with lymphoproliferative malignancy (for celiac disease, HR = 2.82; 95% confidence interval [CI] = 2.36 to 3.37, n = 193; for inflammation, HR = 1.81; 95% CI = 1.42 to 2.31, n = 89), latent celiac disease was not associated with lymphoproliferative malignancy (HR = 0.97; 95% CI = 0.44 to 2.14, n = 7). The absolute rates of lymphoproliferative malignancies among persons with celiac disease, small intestinal inflammation, and latent celiac disease were 70.3 per 100 000 person-years, 83.4 per 100 000 person-years, and 28.0 per 100 000 person-years, respectively. Compared with individuals with celiac disease, individuals with small intestinal inflammation or latent celiac disease were at a statistically significantly lower risk of lymphoproliferative malignancy. Risk of any solid cancer was not increased beyond the first year of follow-up in any cohort. Celiac disease was associated with Hodgkin lymphoma and both T-cell and B-cell non-Hodgkin lymphomas.
Celiac disease is an autoimmune disorder triggered by dietary gluten in genetically susceptible individuals, and it affects about 1% of the population in Europe and North America (1) . The diagnosis of celiac disease requires a small intestinal biopsy with characteristic histological findings, including intraepithelial lymphocytosis, crypt hyperplasia, and villous atrophy (2, 3) . Serological testing has increasingly become an important diagnostic tool in celiac disease, and it is currently under debate whether a biopsy is needed to confirm a celiac disease diagnosis (4) . Some individuals with positive celiac disease serology have a normal mucosa (5) and are defined by the National Institutes of Health Consensus Statement on Celiac Disease as having latent celiac disease (2) . Borderline mucosal changes, such as duodenal or jejunal inflammation including intraepithelial lymphocytosis, are typical in early-stage celiac disease (6) but also occur in other conditions (7) .
Several studies have found a positive association between celiac disease and malignant lymphomas (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) , especially the rare enteropathy-type T-cell lymphoma. Although earlier estimates of risk of non-Hodgkin lymphoma in celiac disease varied greatly, finding no increased risk (19) , a 42-fold increase (10) , or a 69-fold increased risk of death from non-Hodgkin lymphoma (11) , recent data suggest a three-to sixfold increased risk of lymphoma incidence (8, 9, 12, (14) (15) (16) 18) . Most previous reports on celiac disease and lymphoma have been limited by small numbers (10, 12, 14, 20, 21) or may have suffered from selection bias by restricting participants to those at referral centers (10, 12, 14, 15) or to inpatients with celiac disease (8, 13, 16) . Two previous reports investigated the risk of
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Risk of Lymphoproliferative Malignancy in Relation to Small Intestinal Histopathology Among Patients With Celiac Disease
Background
Celiac disease is associated with an increased risk of malignant lymphomas. The risk of lymphoproliferative malignancies in patients with small intestinal inflammation without villous atrophy and in patients with latent celiac disease is unknown.
Methods
We performed a cohort study using duodenal and jejunal biopsy data that were collected from all 28 Swedish pathology departments (July 1969 to February 2008 . We identified two population-based cohorts composed of 28 989 individuals with biopsy-verified celiac disease (villous atrophy, Marsh stage 3) and 13 140 individuals with small intestinal inflammation without villous atrophy (Marsh 1 + 2) and a regional cohort of 3711 individuals with latent celiac disease (positive celiac disease serology and normal mucosa). Cancer data were obtained by linkage to the National Cancer Registry. We used Cox regression to estimate hazard ratios (HRs) for lymphoproliferative malignancy and any solid cancer among the three cohorts compared with a total of 227 911 age-and sex-matched reference individuals. lymphoma in celiac disease when celiac disease was defined solely according to serology (21, 22) . In subanalyses, these studies found elevated but not statistically significantly increased risk among such patients, and lack of statistical significance may have been due to the small size of the study populations (21, 22) . To our knowledge, no previous study has presented risk estimates for malignancy in patients with small intestinal inflammation without villous atrophy or with latent celiac disease.
Therefore, the purpose of this nationwide population-based study was to assess and to compare the risks of lymphoproliferative malignancies overall and by subtype in three cohorts: 1) 28 989 individuals with celiac disease, 2) 13 140 individuals with small intestinal inflammation, and 3) 3711 individuals with latent celiac disease compared with 227 911 age-and sex-matched individuals from the reference cohorts. To determine whether the increased risk of lymphoproliferative malignancy reflected an increased risk of malignancy in general, we also examined the risk of any solid cancer among patients with celiac disease.
Subjects and Methods
All Swedish residents are assigned a unique personal identity number (23) . Through this number we linked data on small intestinal biopsies and serology with data on cancer occurrence. We collected information on all duodenal and all jejunal biopsies in computerized records in any of Sweden's 28 pathology departments from July 1969 to February 2008 from patients with celiac disease (Marsh stage 3; villous atrophy), small intestinal inflammation (Marsh 1 and 2) or normal mucosa (Marsh 0) (Table 1 ) (24, 25) . Data were restricted to computerized biopsy reports, and for this reason, most patients in this study had biopsies after 1990 (Table 1) . In Sweden, all small intestinal biopsies are classified according to the SnoMed system (24) . This grading system uses the same parameters as the Marsh histopathology classification (26) (see Appendix 1) . Diagnosis of celiac disease in this study was based solely on histopathology, and positive celiac disease serology was not required. The majority of the patients with celiac disease had received a SnoMed code for nonspecific villous atrophy. However, in a subset of 10 800 patients, we also had detailed data on the degree of villous atrophy: 3527 patients had partial villous atrophy and 7273 had subtotal or total villous atrophy. For a patient to be classified as having inflammation only, we required at least one biopsy with a SnoMed code of inflammation, equivalent to Marsh 1 or Marsh 2, and no prior or subsequent biopsy with villous atrophy. The Swedish SnoMed grading system does not distinguish between Marsh 1 and 2.
Through the 28 participating pathology departments, we identified 381 043 biopsy reports. We then excluded 28 654 duplicates and 986 reports that contained data irregularities (eg, dated before birth). There remained 351 403 biopsy reports for 287 586 unique individuals. Most of these had a normal biopsy (n = 244 992), and by linking data from a subset of these individuals (n = 121 952) with celiac disease serology data from biochemistry laboratories at eight university hospitals, we identified 3736 individuals with latent celiac disease (25) . In 2007, the catchment areas of these laboratories included both rural and urban areas that included about 49% of the Swedish population (for a list of contributing
CONTEXT AND CAVEATS
Prior knowledge
Although active celiac disease has been associated with villous atrophy and increased risk of lymphomas, it was not known whether individuals with small intestinal inflammation (without villous atrophy) or latent celiac disease (celiac serology, without villous atrophy) were at increased risk.
Study design
Records were collected from Swedish patients who had small intestinal biopsies from 1969 to 2008 and compared with data from the National Cancer Registry. Subjects included 28 989 persons with celiac disease, 13 140 with small intestinal inflammation, and 3711 with latent celiac disease matched with 227 911 age and sexmatched control subjects. Cox proportional hazards models were used to estimate risk of lymphomas and other cancers.
Contribution
Both celiac disease and small intestinal inflammation were associated with approximately twofold increased risk of lymphoma. However, latent celiac disease was not associated with increased risk.
Implications
Among persons with celiac disease, risk of lymphoma depends on the presence of pathological small intestine histology.
Limitations
Positive serology was not required for persons with biopsy-confirmed celiac disease. Persons with latent disease were diagnosed by more recent serological procedures and may not have reached the age of highest cancer incidence. No data were available on smoking habits or adherence to a gluten-free diet.
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biochemistry laboratories, see Appendix 2). For each serology sample, we obtained information on the date of test, the type of test (antigliadin, endomysial, or tissue transglutaminase), antibody levels, and IgG or IgA level at the time of testing. A positive serology test for celiac disease was defined as a positive IgA or IgG antigliadin, endomysial, or tissue transglutaminase test. Individuals with a positive celiac disease serology test less than 180 days before or no later than 30 days after a normal biopsy (and never a biopsy with villous atrophy or inflammation) were regarded as having latent celiac disease (n = 3736) (25) . We excluded 174 individuals in whom the biopsy was suspected to originate from the ileum (29 with celiac disease, 128 with inflammation, and 17 with latent celiac disease), 35 for whom there were data irregularities (23 with celiac disease, 12 with inflammation, and none with latent celiac disease) and 226 individuals who had a diagnosis of lymphoproliferative malignancy before study entry (95 with celiac disease, 123 with inflammation, and eight with latent celiac disease). Finally, 55 individuals (12 with celiac disease, 43 with inflammation, and none with latent celiac disease) had been biopsied after December 31, 2007 , when follow-up ended and were thus excluded. Through Statistics Sweden, we then matched each individual with celiac disease, inflammation, or latent celiac disease with five reference individuals based on age, sex, county of residence, and calendar year of diagnostic biopsy, using data from the Total Population Register (27) .
Our final analyses were based on 28 989 individuals with celiac disease, 13 140 with inflammation, 3711 with latent celiac disease, and 227 911 age-and sex-matched reference individuals (144 220 matched to patients with celiac disease, 65 242 matched to patients with inflammation, and 18 449 matched to patients with latent celiac disease). Cancer data were collected by matching of these cohorts to the Swedish National Cancer Registry (28) . To identify individuals with lymphoproliferative malignancy, we used the International Classification of Diseases-7-codes 200-204, and to identify those with any solid cancer, we used codes 140-199.
From Statistics Sweden, we received data on education from the Education Register. We categorized educational level into four groups: 9 years or less of primary and secondary school, 2 years of high school, 3 years of high school, and college or university studies.
Statistical Methods and Analyses
We used a Cox regression model to estimate hazard ratios (HRs) with 95% confidence intervals (CIs) for lymphoproliferative malignancies. To put the risk of lymphoproliferative malignancies into context, we also estimated the risk of any solid cancer according to small intestinal histopathology ( Table 2 ). All statistical tests were two-sided, and we considered 95% confidence intervals that did not include 1.00 and P values less than .05 to be statistically significant. All analyses were conditioned on risk set, so that an individual in any of the three cohorts was compared only with his or her age-and sex-matched reference individuals. All analyses were adjusted for educational level.
We investigated the proportional hazard assumption with respect to time since biopsy by estimating the hazard ratio for the first year of follow-up, for years 2-5, and for more than 5 years. The cumulative incidence of lymphoproliferative malignancy was estimated by fitting a Cox regression model adjusted for sex, age at biopsy, and calendar year at biopsy (both in 5-year bands) stratified according to the three different disease groups. The cumulative incidences, standardized to the sex, age, and calendar year distribution for all the three groups, were then estimated from the baseline cumulative hazard functions for the different disease groups. Using a similarly adjusted Cox regression model, we also examined whether the risk of lymphoproliferative malignancy in patients with latent celiac disease or small intestinal inflammation was statistically different from that in patients with celiac disease (internal comparison).
The cohorts were event free at the start of follow-up. In separate analyses, we stratified for sex, age, and calendar period at study entry. Follow-up time started on the date of the first positive biopsy for patients with celiac disease or small intestinal inflammation. Follow-up started on the date of the first normal biopsy, with a positive celiac disease serology test less than 180 days before, or no later than 30 days after a normal biopsy, for patients classified as having latent celiac disease. Follow-up started on the corresponding dates for the matched controls. Follow-up time ended when any of the following events occurred: 1) diagnosis of lymphoproliferative malignancy, 2) death, 3) emigration, or 4) December 31, 2007. Moreover, for reference individuals, follow-up ended if they had a biopsy of latent celiac disease, small intestinal inflammation, or villous atrophy. We also calculated absolute excess risk as (1 2 1/HR) × incidence per 100 000 person-years among patients.
In a priori specified complementary analyses, we compared the risk of lymphoproliferative malignancy according to partial vs subtotaltotal villous atrophy. We used SAS version 9.2 (SAS Institute, Cary, NC) to perform the analyses. At a .05 significance level, we had 80% power to detect a relative risk of lymphoproliferative malignancy of 1.39 in celiac disease (inflammation: 1.48; latent celiac disease: 2.45). 
Ethics
Results
This study included 28 989 individuals with celiac disease, 13 140 individuals with small intestinal inflammation, 3711 individuals with latent celiac disease, and 227 911 reference individuals (144 220 matched to patients with celiac disease, 65 242 matched to patients with inflammation, and 18 449 matched to patients with latent celiac disease). The study participants were identified through biopsy records, serology data as well as cancer data from the Swedish national cancer registry. Control subjects were identified from the general population through the Swedish Total Population Register and were matched for age, sex, county of residence, and calendar year of diagnostic biopsy. The majority of study participants were female (Table 1) . Figure 1 ). In the first year of follow-up, there was an increased risk of any solid cancer in patients with celiac disease. This risk increase vanished after 1 year of follow-up ( Table 2 ). The relative risk of lymphoproliferative malignancy was similar in men and women and did not change over successive calendar periods (Table 3 ). There was no increased risk of lymphoproliferative malignancy in children (0-19 years) with celiac disease (HR = 0.75; 95% CI = 0.31 to 1.80; Table 3 ). Celiac disease was positively associated with both non-Hodgkin lymphoma (HR = 4.26; 95% CI = 3.39 to 5.36; absolute excess risk = 40.0 per 100 000 person-years) and Hodgkin lymphoma (HR = 2.73; 95% CI = 1.26 to 5.93; absolute excess risk = 2.3 per 100 000 person-years) ( Table 4) . We also found an increased risk of both T-cell and B-cell non-Hodgkin lymphoma, but no increased risk of myeloma, acute or chronic lymphocytic leukemia (Table 4 ). In individuals with celiac disease, the risk of non-Hodgkin lymphoma was still substantially increased beyond the first year of follow-up (HR = 2.93; 95% CI = 2.23 to 3.85), while the hazard ratio for Hodgkin lymphoma decreased to 1.54 (95% CI = 0.56 to 4.23). The degree of villous atrophy in celiac disease did not influence the risk of lymphoproliferative malignancy (P =.54). Overall results were similar without adjustment for education (data not shown).
Celiac Disease
Small Intestinal Inflammation
There were 89 lymphoproliferative malignancies during 106 699 person-years in individuals with inflammation vs 278 such malignancies during 569 128 person-years in reference individuals (the absolute rates were 83.4 vs 48.9 per 100 000 person-years). Individuals with inflammation were at an increased risk of lymphoproliferative malignancy (HR = 1.81; 95% CI = 1.42 to 2.31; Table  2) , with an absolute excess risk of 34.6 per 100 000 person-years. The risk estimate for lymphoproliferative malignancy was highest * Data adjusted for education. Educational level was categorized into four groups: 9 years or less of primary and secondary school, 2 years of high school, 3 years of high school, and college or university studies. Individuals with celiac disease, inflammation, or latent celiac disease were each matched with five reference individuals based on age, sex, county of residence, and calendar year of diagnostic biopsy. CI = confidence interval; HR = hazard ratio. † The number of positive events, that is, malignancies, in reference individuals ("reference cohorts") refers to the total number of malignancies in individuals matched to patients with celiac disease, inflammation, or latent celiac disease. When hazard ratios were calculated, individuals with celiac disease were only compared with their reference cohort, whereas individuals with inflammation were compared with their reference cohort and so on.
during the first year after biopsy, but the excess risk vanished with more than 5 years of follow-up (Table 2 ). For patients with small intestinal inflammation, risks were similar for men and women (Table 3) , and risk estimates were increased for non-Hodgkin lymphoma (HR = 1.86; 95% CI = 1.32 to 2.60) but not for Hodgkin lymphoma (HR = 0.94; 95% CI = 0.21 to 4.21) ( Table 4 ). The risk of any solid cancer was increased only in the first year of follow-up (Table 2) .
Latent Celiac Disease
During follow-up, there were seven lymphoproliferative malignancies among 3711 individuals with latent celiac disease (25 010 person-years), as compared with 39 among 18 339 reference individuals (125 283 person-years). The absolute rates were 28.0 vs 31.1 per 100 000 person-years in latent celiac subjects compared with control subjects, respectively. Latent celiac disease was not associated with lymphoproliferative malignancy (HR = 0.97; 95% CI = 0.44 to 2.14, Table 2 ). All seven lymphoproliferative malignancies occurred among the 3353 individuals with positive antigliadin antibodies, and none of the 358 individuals with normal mucosa and positive IgA endomysial or IgA tissue transglutaminase antibodies had a record of a lymphoproliferative malignancy.
Internal Comparison Among Individuals Undergoing Biopsy
The purpose of the internal comparison presented in Figure 1 was to estimate the cumulative incidence over time standardized for 
Discussion
To our knowledge, this is the largest study of celiac disease and lymphoproliferative malignancy to date, and the first to present relative risks on such malignancies in individuals with inflammation and latent celiac disease. The risk of lymphoproliferative malignancy was dependent on the presence of histologically verifiable pathology, and the positive association with biopsy-verified celiac disease remained evident after 5 years of follow-up. By contrast, the risk of solid cancer was independent of histopathology and the excess risk vanished after the first year of follow-up. It is possible that the increased risk of solid cancer in the first year is due to confounding by indication, such that investigation for one of the conditions may have resulted in diagnosis of the other. Such bias could potentially also explain the positive association between latent celiac disease and lymphoproliferative malignancy in the first year of follow-up.
The main finding of this study was the lack of association between latent celiac disease and lymphoproliferative malignancy. Although our study included fewer individuals with latent celiac disease than with inflammation or celiac disease, the observed number of lymphoproliferative malignancies in patients with latent celiac disease (n = 7) was practically the same as expected (7.2). Although precision was limited by the size of the cohort, these results are consistent with a low risk of lymphoproliferative malignancy as indicated by a hazard ratio close to 1.00. We also note that the risk of lymphoproliferative malignancy in patients with latent celiac disease was statistically significantly lower compared with that in patients with biopsy-verified celiac disease (HR = 0.38; 95% CI = 0.18 to 0.82).
Among patients with latent celiac disease, all lymphoproliferative malignancies occurred in individuals with positive antigliadin antibodies. Although the specificity of antigliadin antibodies is lower than that of transglutaminase and endomysial antibodies, it is still high (93%-94%) (29) . The lack of lymphoproliferative malignancies among individuals with positive transglutaminase and endomysial antibodies should not be interpreted as if presence of positive transglutaminase and endomysial antibodies protects against lymphoproliferative malignancies but does argue against a large increased risk of such malignancies in those individuals. Our negative findings in latent celiac disease suggest that celiac disease serology alone cannot predict the future risk of lymphoproliferative malignancy.
Patients with small intestinal inflammation were at increased risk of lymphoproliferative malignancies, especially non-Hodgkin lymphoma. Small intestinal inflammation is a heterogeneous condition and does not fulfill the criteria for celiac disease. It is a mixture of both acute and chronic inflammation. This might explain why risk estimates for individuals with small intestinal inflammation are lower than those for individuals with celiac disease, in whom chronic inflammation is present until diagnosis. Although small intestinal inflammation may represent early-stage celiac * Data adjusted for education. Educational level was categorized into four groups: 9 years or less of primary and secondary school, 2 years of high school, 3 years of high school, and college or university studies. Individuals with celiac disease, inflammation, or latent celiac disease were each matched with five reference individuals based on age, sex, county of residence, and calendar year of diagnostic biopsy. CI = confidence interval; HR = hazard ratio. † The number of positive events, that is, malignancies, in reference individuals ("reference cohorts") refers to the total number of malignancies in individuals matched to patients with celiac disease, inflammation, or latent celiac disease. When hazard ratios were calculated, individuals with celiac disease were only compared with their reference cohort, whereas individuals with inflammation were compared with their reference cohort and so on.
disease, it can also be due to a number of other conditions including Helicobacter pylori infection or giardiasis (7). However, despite the heterogeneity of the condition, when 1534 Swedish biopsy reports of inflammation or villous atrophy were manually reviewed, only fewer than 5% of the individuals with inflammation had a disorder other than celiac disease mentioned on the biopsy report (24) . This study confirms and extends earlier reports of an increased risk of lymphoproliferative malignancy in celiac disease. In this study, people with diagnosed celiac disease had modestly increased risk of lymphoproliferative malignancies and the risk estimates were lower than most previous studies. However, the increased risk estimates of lymphoproliferative malignancy in our study were consistent during follow-up and remained statistically significant also after 5 years of follow-up. In persons with celiac disease, we found an increased risk of both the T-cell and B-cell types of nonHodgkin lymphoma, as well as of Hodgkin lymphoma. Our findings of a highly increased risk of T-cell non-Hodgkin lymphoma confirm and add to previous reports (12, 13, 17, 18) because we studied large numbers of persons with celiac disease and used a non selected population-based cohort. We were also able to show an almost twofold increased risk of B-cell lymphomas, which is consistent with our previous report (13) .
One of the strengths of this study is the internal comparison of celiac disease vs small intestinal inflammation or latent celiac disease. In this analysis, there was a statistically significantly increased risk of lymphoproliferative malignancy in persons with celiac disease compared with other individuals undergoing small intestinal biopsy. This constitutes strong evidence that the risk of lymphoproliferative malignancy in celiac disease is dependent on small intestinal histopathology and that surveillance bias introduced due to small intestinal investigation was not responsible for our findings. Another strength is that we were able to minimize selection bias by ascertainment of celiac disease through biopsy data: small intestinal biopsy is standard clinical practice for celiac disease diagnosis in Sweden (2, 3, 24) .
A potential weakness in our study is that we did not require positive serology data or certain clinical features for the diagnosis of celiac disease. However, in a previous study to validate villous atrophy in Swedish biopsy registers, 71 (88%) of the 81 individuals with biopsy-confirmed celiac disease (villous atrophy) also had positive celiac disease serology before the diagnostic biopsy (24) . Manual review of the charts of 114 randomly selected individuals with villous atrophy showed that 108 (95%) of the 114 had clinical celiac disease (24) . Although villous atrophy has a high sensitivity for diagnosed celiac disease (24) , some individuals with diagnosed celiac disease may not have been identified in this study (eg, those biopsied before the computerization of biopsy records). A potential nondifferential misclassification of celiac disease may have acted to attenuate relative risk estimates to a small degree but should not have created any false-positive associations. In addition, it should be noted that we examined risk of malignancy in individuals undergoing small intestinal biopsy and that we cannot estimate the risk of malignancy in undiagnosed celiac disease.
Celiac disease serology did not come into routine use in Sweden until the 1990s. This has restricted the length of follow-up in the cohort of latent celiac disease, and it should be noted that most individuals in our study who were diagnosed with latent celiac disease had not yet reached ages of high cancer incidence at the end of follow-up. Also, we did not have any information on smoking. This is, however, unlikely to explain the positive association between lymphoproliferative malignancy and celiac disease because celiac disease is negatively (30) or not at all associated (31) with smoking and adjustment for smoking in earlier studies of celiac disease and malignancy (9) has not influenced risk estimates. As in all observational studies, we cannot rule out the existence of any unidentified potential confounders. This study had no data on dietary adherence; and we cannot rule out that the risk increase for lymphoproliferative malignancy in celiac disease was restricted to individuals consuming gluten. In a subset of individuals with celiac disease, a patient chart validation found signs of low dietary adherence in 17% (24) . Although we lacked data on dietary adherence, two findings suggest an association between a gluten-free diet and reduced lymphoproliferative malignancy. First, although celiac disease diagnosed in adulthood was associated with lymphoproliferative malignancy, celiac disease diagnosed in childhood was not. This is compatible with the hypothesis that an early introduction of a gluten-free diet is associated with less villous atrophy and fewer disease-related effects. Second, individuals with latent celiac disease (ie, without any mucosal damage) were not at increased risk of lymphoproliferative malignancy, and dietary adherence among persons with celiac disease is likely to result in an intestinal mucosa resembling that of latent celiac disease.
In conclusion, in this large population-based study of celiac disease, the risk of lymphoproliferative malignancy was dependent on the histopathological appearance of the small intestine. Although individuals with biopsy-verified celiac disease were at increased risk of lymphoproliferative malignancy, individuals with latent celiac disease were not. This finding suggests that positive celiac disease serology alone cannot predict future risk of lymphoproliferative malignancy. 
